Cargando…

Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series

Objectives. B cell depletion is an effective treatment strategy in ANCA-associated vasculitis (AAV). Ofatumumab is a fully humanized anti-CD20 mAb that has shown efficacy in the treatment of haematological malignancy and RA. The use of ofatumumab in the treatment of AAV has not previously been repor...

Descripción completa

Detalles Bibliográficos
Autores principales:	McAdoo, Stephen P., Bedi, Rachna, Tarzi, Ruth, Griffith, Megan, Pusey, Charles D., Cairns, Thomas D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957674/ https://www.ncbi.nlm.nih.gov/pubmed/27094598 http://dx.doi.org/10.1093/rheumatology/kew199

Ejemplares similares

ANCA Associated Vasculitis Subtypes: Response [Response to Letter]
por: Austin, Keziah, et al.
Publicado: (2022)

ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives
por: Austin, Keziah, et al.
Publicado: (2022)

Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series
por: McAdoo, Stephen P., et al.
Publicado: (2015)

Recent advances in understanding of the pathogenesis of ANCA-associated vasculitis
por: Prendecki, Maria, et al.
Publicado: (2018)

Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis
por: McAdoo, Stephen P, et al.
Publicado: (2019)

Management of ANCA-associated vasculitis: Current trends and future prospects
por: Hamour, Sally, et al.
Publicado: (2010)

Danger-associated molecular pattern molecules and the receptor for advanced glycation end products enhance ANCA-induced responses
por: Page, Theresa H, et al.
Publicado: (2021)

B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis
por: Lundberg, Sigrid, et al.
Publicado: (2017)

Long- term outcome of paediatric patients with ANCA vasculitis
por: Arulkumaran, Nishkantha, et al.
Publicado: (2011)

Serum chitinase-3-like 1 protein is a useful biomarker to assess disease activity in ANCA-associated vasculitis: an observational study
por: Ahn, Sung Soo, et al.
Publicado: (2021)

ANCA Vasculitis Induction Management During the COVID-19 Pandemic
por: Salas, Antonio, et al.
Publicado: (2021)

Membranous Glomerulonephritis With Crescents
por: Nikolopoulou, Aikaterini, et al.
Publicado: (2019)

Bacterial endocarditis associated with proteinase 3 anti-neutrophil cytoplasm antibody
por: McAdoo, Stephen P., et al.
Publicado: (2011)

Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model
por: McAdoo, Stephen P., et al.
Publicado: (2020)

Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients
por: McAdoo, Stephen P., et al.
Publicado: (2017)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

Anti–glomerular basement membrane disease during the COVID-19 pandemic
por: Prendecki, Maria, et al.
Publicado: (2020)

Current and future prospects in the management of granulomatosis with polyangiitis (Wegener’s granulomatosis)
por: Tarzi, Ruth M, et al.
Publicado: (2014)

Animal Models of ANCA Associated Vasculitis
por: Shochet, Lani, et al.
Publicado: (2020)

ANCA-associated vasculitis in Ireland: a multi-centre national cohort study
por: Scott, Jennifer, et al.
Publicado: (2022)

Glomerulonephritis and autoimmune vasculitis are independent of P2RX7 but may depend on alternative inflammasome pathways
por: Prendecki, Maria, et al.
Publicado: (2022)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-associated vasculitis of the appendix
por: Leaver, Phillip J, et al.
Publicado: (2019)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Prendecki, Maria, et al.
Publicado: (2022)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
por: Wallace, Zachary S., et al.
Publicado: (2019)

Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis
por: Pepper, Ruth J, et al.
Publicado: (2013)

Progress in treatment of ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2012)

Eye involvement in ANCA positive vasculitis
por: Macarie, Sorin Simion, et al.
Publicado: (2020)

Mechanisms of thrombosis in ANCA-associated vasculitis
por: Misra, Durga Prasanna, et al.
Publicado: (2021)

Granulomatous Inflammation in ANCA-Associated Vasculitis
por: Müller, Antje, et al.
Publicado: (2021)

Complement Inhibition in ANCA-Associated Vasculitis
por: Tesar, Vladimir, et al.
Publicado: (2022)

The involvement of NETs in ANCA-associated vasculitis
por: Shiratori-Aso, Satoka, et al.
Publicado: (2023)

Ocular disease in patients with ANCA-positive vasculitis
por: Watkins, Angela S., et al.
Publicado: (2009)

Experimental crescentic glomerulonephritis: a new bicongenic rat model
por: D’Souza, Zelpha, et al.
Publicado: (2013)

Prevalence of large vessel vasculitis in ANCA-associated vasculitis: a retrospective cohort study
por: Coattrenec, Yann, et al.
Publicado: (2021)

Clinicopathologic Findings in Mass Forming ANCA-Associated Vasculitis
por: Gilani, Sarwat I., et al.
Publicado: (2022)

Pathophysiology of ANCA-Associated Small Vessel Vasculitis
por: Kallenberg, Cees G. M.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_cof2n0naughhpkjclvbnljm724